Literature DB >> 10906740

Partial sequencing and tissue distribution of the canine isoforms of steroid 5alpha-reductase type I and type II.

P N Span1, A van Bokhoven, A G Smals, C G Sweep, J A Schalken.   

Abstract

BACKGROUND: The dog is regarded to be a valid model to test the effects of 5alpha-reductase inhibitors on prostatic growth. However, limited information is available on the characteristics or even existence of 5alpha-reductase isozymes in this species.
METHODS: Here, we set out to clone the cDNA of the dog isoforms of 5alpha-reductase type I and type II by a degenerate cloning strategy and to assess the tissue distribution of both transcripts and the enzymatic activity of the isozymes.
RESULTS: We identified two clones with homology to the human 5alpha-reductase isoforms type I and type II to be expressed in dog prostate. At the amino-acid level, these partial clones were found to exhibit a homology with their human counterparts of 83% and 88%, respectively. The expression levels of 5alpha-reductase mRNA were screened by RT-PCR in a number of dog tissues. No correlation was found between tissue mRNA expression and enzymatic 5alpha-reductase activities.
CONCLUSIONS: The present study describes the partial cloning of the dog 5alpha-reductase isozymes and their tissue distribution. These results provide additional data for the use of the dog as an animal model to investigate the role of 5alpha-reductase isozymes in steroid metabolism. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906740     DOI: 10.1002/1097-0045(20000801)44:3<233::aid-pros8>3.0.co;2-c

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  1 in total

1.  Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.

Authors:  Zhiyi Yao; Yingjun Xu; Minmin Zhang; Sheng Jiang; Marc C Nicklaus; Chenzhong Liao
Journal:  Bioorg Med Chem Lett       Date:  2010-10-28       Impact factor: 2.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.